article · Best Practice & Research Clinical Obstetrics & Gynaecology
Preeclampsia presents as a complex condition with diverse clinical phenotypes that complicate diagnosis and treatment. Early-onset preeclampsia is primarily characterised by placental dysfunction stemming from inadequate remodelling of uterine spiral arteries, leading to mal-perfusion and syncytiotrophoblast stress. In contrast, late-onset preeclampsia is probably caused by placental overgrowth or premature senescence. Rising rates of obesity, diabetes, multifetal pregnancies, and advanced maternal age have driven an increase in preeclampsia frequency over recent decades. Predicting the condition effectively relies on multimodal tools combining clinical risk factors, biomarkers, and sonography. Aspirin represents the most effective preventative measure for early-onset cases. Because socioeconomic and cultural factors significantly influence incidence and clinical severity, managing preeclampsia and eclampsia requires collaborative multi-sector partnerships.
Preeclampsia and eclampsia pose severe threats to maternal survival and wellbeing. Understanding the distinct biological mechanisms behind early- and late-onset forms helps healthcare systems target interventions more accurately. As population risk factors such as obesity and diabetes become more widespread, utilising multimodal predictive screening, preventative aspirin, and multi-sector healthcare strategies becomes vital to reducing maternal morbidity and mortality.
The abstract highlights the application of multimodal predictive tools that combine maternal risk factors, biomarkers, and sonography to guide early intervention with aspirin. These tools target healthcare providers and diagnostic clinicians managing maternal health. However, the text describes existing clinical indicators and general management strategies rather than a specific new proprietary product or commercialisation pathway.
AI-generated from the published abstract. Always read the original work before citing.
Preeclampsia (PE) is a complex heterogeneous disorder with overlapping clinical phenotypes that complicate diagnosis and management. Although several pathophysiological mechanisms have been proposed, placental dysfunction due to inadequate remodelling of uterine spiral arteries leading to mal-perfusion and syncytiotrophoblast stress is recognized as the unifying characteristic of early-onset PE. Placental overgrowth and or premature senescence are probably the causes of late-onset PE. The frequency of PE has increased over the last few decades due to population-wide increases in risk factors viz. obesity, diabetes, multifetal pregnancies and pregnancies at an advanced maternal age. Whilst multimodal tools with components comprising risk factors, biomarkers and sonography are used for predicting PE, aspirin is most effective in preventing early-onset PE. The incidence and clinical consequences of PE and eclampsia are influenced by socioeconomic and cultural factors, therefore management strategies should involve multi-sector partnerships to mitigate the adverse outcomes.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.bpobgyn.2024.102473
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
